Population biology, evolution, and immunology of vaccination and vaccination programs

American Journal of the Medical Sciences

Volumn 315, Issue 2, 1998, Pages 76-86

  Halloran, M E ^a   Anderson, R M ^f   Azevedo Neto, R S ^f   Bellini, W J ^c   Branch, O ^c   Burke, M A ^a   Compans, R ^b   Day, K ^f   Gooding, L ^b   Gupta, S ^f   Katz, J ^c   Kew, O ^c   Keyserling, H ^b   Krauser, R ^d   Lal, A A ^c   Massad, E ^f   McLean, A R ^f   Rosa, P ^e   Rota, P ^c   Wiener, P ^c   Wynn, S G ^b   Zanetta, D M T ^a   more..

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d Fogarty Institute   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f Rollins School of Public Health ^*

Author keywords

Immunology; Modeling; Populations; Vaccines

Indexed keywords

AGING; ANTIBODY RESPONSE; CONFERENCE PAPER; EVOLUTION; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOLOGY; MATHEMATICAL MODEL; POPULATION RESEARCH; PROPHYLAXIS; SAMPLING; VACCINATION; VACCINE PRODUCTION;

EID: 0031912841     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199802000-00003     Document Type: Conference Paper

References (51)

1. Lennon JL, Black FL. Maternally derived measles immunity in the era of vaccine protected mothers. J Pediatr. 1986;108:671-6.
2. Pabst HF, Spady DW, Marusyk RG, Carson MM, Chui LW, Joffres MR, Grimsrud KM. Reduced measles immunity in infants in a well-vaccinated population. Pediatr Infect Dis J. 1992;11:525-9.
3. Mulholland K. Measles and pertussis in developing countries with good vaccine coverage. Lancet. 1995;345:305-7.
4. McLean AR. After the honeymoon in measles control. Lancet. 1995;345:272.
5. Halloran ME, Struchiner CJ, Watelet L. Epidemiologic effects of vaccines with complex effects in an age-structured population. Math Biosci. 1994;121:193-225.
6. Rouderfer V, Becker NG, Hethcote HW. Waning immunity and its effects on vaccine schedules. Math Biosci. 1994;124:59-82.
7. Mosier DE, Gulizia RJ, MacIsaac PD, Corey L, Greenberg PD. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. Proc Natl Acad Sci U S A. 1993;90:2443-7.
8. Michie CA and Harvey D. Can expression of CD45RO, a T cell surface molecule, be used to detect congenital infection? Lancet. 1994;343:1259-60.
9. Mestecky J, Moldoveanu Z, Novak M, Compans RW. Mucosal immunity and strategies for novel microbial vaccines. Acta Paediatrica Japonica. 1994;36:537-44.
10. Holmgren J, Lycke N, Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector system. Vaccine. 1993;11:1179-84.
11. Kikuta K, Hirabayashi Y, Nagamine T, et al. Cross-protection against influenza B type virus infection by intranasal inoculation of the HA vaccines combined with cholera toxin B subunit. Vaccine. 1990;8:595-9.
12. Mason HS, Lam DMK, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci U S A. 1992;89(11):745-9.
13. Powers DC. Immunological principles and emerging strategies of vaccination for the elderly. J Am Geriat Soc. 1992;40:81-94.
14. Halloran ME, Cochi S, Lieu T, Wharton M, Fehrs LJ. Theoretical epidemiologic and morbidity effects of routine immunization of preschool children with live-virus varicella vaccine in the U.S. Am J Epidemiol. 1994;140:81-104.
15. McLean AR and Michie CA. In vivo estimates of division and death rates of human T lymphocytes. Proc Natl Acad Sci USA. 1995;92:3707-11.
16. Michie CA, McLean AR, Alcock C, Beverley PCL. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature. 1992;360:264-5.
17. Franceschi C, Monti D, Sansoni P, Cossarizza A. The immunology of exceptional individuals: the lesson of centenarians. Immunol Today. 1995;16:12-16.
18. Andersen RM. The Croonian Lecture, 1994. Populations, infectious disease and immunity: a very nonlinear world. Philos Trans R Soc Lond B Biol Sci. 1994;346:457-505.
19. Francis T Jr. On the doctrine of original antigenic sin. Proc Am Philos Soc. 1960;104:572-8.
20. Hill AVS, Allsopp CEM, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, et al. Common West African HLA antigens are associated with protection from severe malaria. Nature. 1991;352:595-600.
21. Hill AVS, Elvin J, Willis AC, Aidoo M, Allsopp CEM, Gotch FM, et al. Molecular analysis of the association of HLA-b53 and resistance to severe malaria. Nature. 1992;360:434-9.
22. Gupta S, Swinton J, Anderson RM. Theoretical studies of the effects of heterogeneity in the parasite population on the transmission dynamics of malaria. Proc R Soc Lond B Biol Sci. 1994;256:231-8.
23. Kim HW, Canchola JG, Brandt CD, Pyles G. Respiratory virus disese in infants despite prior administration of inactivated vaccine. Am J Epidemiol. 1969;89:422-34.
24. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science. 1988;239:476-81.
25. Forsyth KP, Anderson RF, Kemp DJ, Alpers MP. New approaches to the serotypic analysis of the epidemiology of plasmodium falciparum. In: Anderson RM, Thresh JM, eds. The Epidemiology and Ecology of Infectious Disease Agents. London: The Royal Society; 1988:159-65.
26. Halloran ME, Struchiner CJ, Spielman A. Modeling malaria vaccines II: population effects of stage-specific malaria vaccines dependent on natural boosting. Math Biosc. 1989;94:115-49.
27. Jacquez JA, Koopman JS, Simon CP, Longini IM. The role of primary infection in the epidemics of HIV infection in gay cohorts. J AIDS. 1994;7:1169-84.
28. Edmonson MB, Addiss DG, McPherson T, Berg JL, Circo SR, Davis JP. Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population. J Am Med Assoc. 1990;263:2467-71.
29. Erdman DD, Heath JL, Watson JC, Markowitz LE, Bellini WJ. Immunoglobulin M antobody response to measles virus following primary and secondary vaccination and natural virus infection. J Med Virol. 1993;41:44-8.
30. Halloran ME, Struchiner CJ. Causal inference for infectious diseases. Epidemiology. 1995;6:142-51.
31. Cusi MG, Valensin PE, Cellesi C. Possibility of reinfection after immunisation with RA 27/3 live attenuated rubella virus. Archives of Virology. 1993;129:337-40.
32. Morgan-Capner P, Burgess C, Ireland RM, Sharp JC. Clinically apparent rubella reinfection with a detectable rubella specific IgM response. Brit Med J. 1983;286:1616.
33. Azevedo-Neto RS, Richards A, Nokes DJ, Silveira ASB, Cohen BJ, Passos SD, et al. Salivary antibody detection in epidemiological surveys: a pilot study after a mass vaccination campaign against rubella in São Paulo, Brazil. Trans R Soc Trop Med Hyg. 1995;89:115-8.
34. Francis DP, Hadler SC, Thompson SE, Maynard JE, Ostrow DG, Altman N, et al. The prevention of hepatitis B with vaccine: report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Annals of Intern Med. 1982;97:362-6.
35. Knox EG. Evolution of rubella vaccine policy for the UK. Int J Epidemiol. 1987;16:569-78.
36. Anderson RM, May RM. Infectious Diseases of Human: Dynamics and Control. Oxford: Oxford University Press; 1991.
37. Azevedo-Neto RS, Silveira ASB, Nokes DJ, Yang HM, Passos SD, Cardoso MRA, et al. Rubella seroepidemiology in a non-immunized population of Sao Paulo State, Brazil. Epidemiol Infect. 1994;113:161-73.
38. Coutinho FAB, Massad E, Burattini MN, Yang HM, Azavedo-Neto RS. Effects of vaccination programmes on transmission rates of infections and related threshold conditions for control. IMA J Math Appl Med Biol. 1993;10:187-206.
39. Massad E, Azevedo-Neto RS, Burattini MN, Zanetta DMT, Coutinho FAB, Yang HM, et al. Assessing the efficacy of a vaccination strategy against rubella in Sao Paulo, Brazil. Int J Epidemiol. 1995;24:842-50.
40. Massad E, Burattini MN, Azevedo-Neto RS, Yang HM, Coutinho FAB, Zanetta DMT. A model-based design of a vaccination strategy against rubella in a non-immunized community of Sao Paulo State, Brazil. Epidemiol Infect. 1994;112:579-94.
41. Gupta S, Trenholme K, Anderson RM, Day KP. Antigenic diversity and the transmission dynamics of plasmodium falciparum. Science. 1994;263:961-3.
42. Bellini WJ, Rota JS, Rota PA. The biology of measles virus. J Infect Dis. 1994;170(Suppl1):S15-S23.
43. Rota JS, Wang ZD, Rota PA, Bellini WJ. Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. Virus Research. 1994;31:317-30.
44. Rota PA, Bloom AE, Vanchiere JA, Bellini WJ. Evolution of the nucleoprotein and matrix genes of wild-type strains of measles virus isolated from recent epidemics. Virology. 1994;198:724-30.
45. Tamin A, Rota PA, Wang ZD, Heath JL, Anderson LJ, Bellini WJ. Antigenic analysis of current wild type and vaccine strains of measles virus. J Infect Dis. 1994;170:795-801.
46. Cox NJ, Brammer TL, Regnery HL. Influenza: global surveillance for epidemic and pandemic variants. Eur J Epidemiol. 1994;10:467-70.
47. Hunter RL, Lal AA. Copolymer adjuvants in malaria vaccine development. Am J Trop Med Hyg. 1994;50(Suppl4):52-8.
48. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JAC, Robinson HL. DNA vaccines: protective immunization by parenteral, mucosal and gene-gun inoculations. Proc Natl Acad Sci USA. 1993;90(11):478-82.
49. Nowak MA, May RM, Phillips RE, et al. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature. 1995;375:606-7.
50. McLean AR, Blower SM. Imperfect vaccines and herd immunity to HIV. Proc R Soc Lond B Biol Sci. 1993;253:9-13.
51. Nee S, May RM. Dynamics of metapopulations: habitat destruction and competitive coexistence. J Anim Ecol. 1992;61:37-40.